DNMT1 and hepatocellular carcinoma: Liu et al. also demonstrated that the PD-L1/DNMT1 axis plays a role in sorafenib resistance in HCC, and inhibiting both PD-L1 and DNMT1 expression could restore the sensitivity of cells to sorafenib28.